Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Total Liabilities for 7 consecutive years, with $149.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 4.94% to $149.4 million in Q4 2025 year-over-year; TTM through Nov 2025 was $149.4 million, a 4.94% increase, with the full-year FY2025 number at $149.4 million, up 4.94% from a year prior.
  • Total Liabilities was $149.4 million for Q4 2025 at Nurix Therapeutics, down from $150.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $155.1 million in Q4 2023 to a low of $74.4 million in Q3 2023.
  • A 5-year average of $127.3 million and a median of $133.0 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 94.72% in 2021, then tumbled 36.32% in 2023.
  • Nurix Therapeutics' Total Liabilities stood at $134.5 million in 2021, then fell by 15.92% to $113.1 million in 2022, then surged by 37.18% to $155.1 million in 2023, then fell by 8.22% to $142.4 million in 2024, then grew by 4.94% to $149.4 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Total Liabilities are $149.4 million (Q4 2025), $150.2 million (Q3 2025), and $144.0 million (Q2 2025).